References
- Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223–41.
- Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254–9.
- Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJB, Offer M, et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol 2010;148:760–7.
- Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 2010;468:93–7.
- Milde R, Ritter J, Tennent GA, Loesch A, Martinez FO, Gordon S, Pepys MB, et al. Multinucleated giant cells are specialized for complement-mediated phagocytosis and large target destruction. Cell Rep 2015;13:1937–48.
- Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015;373:1106–14.
- Pepys MB, Cookson LM, Barton SV, Berges AC, Lane T, Hutt D, Fontana M, et al. Dose-dependent progressive immunotherapeutic clearance of systemic amyloid deposits by repeated doses of antibody to serum amyloid P component (SAP). Blood 2015;126:1836.